The BCR-ABL Quantitative IS RQ, Real-Time PCR Test measures the BCR-ABL gene transcript levels, helping monitor and manage Chronic Myeloid Leukemia (CML) and related hematological conditions. This test provides precise insights into the effectiveness of tyrosine kinase inhibitor therapy and disease progression. This test is a gold standard for monitoring minimal residual disease (MRD) in CML patients, ensuring treatment effectiveness.

High BCR-ABL Levels: May indicate poor response to therapy or disease progression. Low/Undetectable BCR-ABL Levels: Suggest effective treatment response or remission. Conditions Monitored: Chronic Myeloid Leukemia (CML) Minimal Residual Disease (MRD) Resistance to tyrosine kinase inhibitors Consult your oncologist for a detailed interpretation and treatment adjustments based on results.

Test price for other cities